Literature DB >> 16812949

Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.

Stefan Kropp1, Ralf Lichtinghagen, Kathrin Winterstein, Jann Schlimme, Udo Schneider.   

Abstract

We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia. 229 patients were genotyped by real-time PCR hybridization probe melting curve technique for CYP2C19*2, CYP2D6*3, *4, and *6, respectively. The gene deletion CYP2D6*5 was analyzed by a long PCR method. Detailed clinical information was obtained from 53 subjects. Patients genotyped homozygous or heterozygous for those CYP2D6 and CYP2C19 poor metabolizer alleles were treated for a longer time in hospital (median 57.5 vs. 40.0 days). Psychiatric patients might benefit from CYP genotyping, the duration of stay as inpatient might be reduced by a priori selection of the appropriate drug for the individual patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16812949

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  8 in total

Review 1.  Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.

Authors:  Chaitali Ghosh; Vikram Puvenna; Jorge Gonzalez-Martinez; Damir Janigro; Nicola Marchi
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

2.  The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.

Authors:  Jochem G Gregoor; Karen van der Weide; Jan van der Weide; Harold J G M van Megen; Antoine C G Egberts; Eibert R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

3.  Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.

Authors:  Gualberto Ruaño; Bonnie L Szarek; David Villagra; Krystyna Gorowski; Mohan Kocherla; Richard L Seip; John W Goethe; Harold I Schwartz
Journal:  Biomark Med       Date:  2013-06       Impact factor: 2.851

4.  CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters?

Authors:  Jorge Duconge; Carmen L Cadilla
Journal:  Biomark Med       Date:  2013-12       Impact factor: 2.851

Review 5.  Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?

Authors:  Lara E Sucheston-Campbell; Alyssa Clay; Philip L McCarthy; Qianqian Zhu; Leah Preus; Marcelo Pasquini; Kenan Onel; Theresa Hahn
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

6.  A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.

Authors:  Elizabeth J J Berm; Judith J Gout-Zwart; Jos Luttjeboer; Bob Wilffert; Maarten J Postma
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

7.  Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6.

Authors:  Paul Y Takahashi; Euijung Ryu; Jyotishman Pathak; Gregory D Jenkins; Anthony Batzler; Matthew A Hathcock; John Logan Black; Janet E Olson; James R Cerhan; Suzette J Bielinski
Journal:  Pharmgenomics Pers Med       Date:  2017-02-14

8.  CYP2D6 genotypes in revolving door patients with bipolar disorders: A case series.

Authors:  Davide Seripa; Madia Lozupone; Giuseppe Miscio; Eleonora Stella; Maddalena La Montagna; Carolina Gravina; Maria Urbano; Lazzaro di Mauro; Antonio Daniele; Antonio Greco; Giancarlo Logroscino; Francesco Panza; Antonello Bellomo
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.